| Product Code: ETC10601262 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Human Microbiome-Based Drugs and Diagnostics Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Human Microbiome-Based Drugs and Diagnostics Market - Industry Life Cycle |
3.4 Ireland Human Microbiome-Based Drugs and Diagnostics Market - Porter's Five Forces |
3.5 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Drug Category, 2021 & 2031F |
3.6 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Diagnostic Category, 2021 & 2031F |
3.7 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Target Organism, 2021 & 2031F |
3.8 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By Application Area, 2021 & 2031F |
3.9 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume Share, By End Use, 2021 & 2031F |
4 Ireland Human Microbiome-Based Drugs and Diagnostics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about the importance of the human microbiome in healthcare |
4.2.2 Growing research and development activities in the field of microbiome-based drugs and diagnostics |
4.2.3 Rising prevalence of chronic diseases driving the demand for innovative treatment options |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for microbiome-based products |
4.3.2 Limited reimbursement policies for microbiome-based drugs and diagnostics |
4.3.3 High cost associated with research and development of microbiome-based therapies |
5 Ireland Human Microbiome-Based Drugs and Diagnostics Market Trends |
6 Ireland Human Microbiome-Based Drugs and Diagnostics Market, By Types |
6.1 Ireland Human Microbiome-Based Drugs and Diagnostics Market, By Drug Category |
6.1.1 Overview and Analysis |
6.1.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Drug Category, 2021 - 2031F |
6.1.3 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Probiotics, 2021 - 2031F |
6.1.4 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Prebiotics, 2021 - 2031F |
6.1.5 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Symbiotics, 2021 - 2031F |
6.1.6 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Fecal Transplant, 2021 - 2031F |
6.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market, By Diagnostic Category |
6.2.1 Overview and Analysis |
6.2.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Microbial Profiling, 2021 - 2031F |
6.2.3 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Microbial DNA Testing, 2021 - 2031F |
6.2.4 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Polymerase Chain Reaction (PCR), 2021 - 2031F |
6.2.5 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Genomic Profiling, 2021 - 2031F |
6.3 Ireland Human Microbiome-Based Drugs and Diagnostics Market, By Target Organism |
6.3.1 Overview and Analysis |
6.3.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Gut Microbiome, 2021 - 2031F |
6.3.3 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Oral Microbiome, 2021 - 2031F |
6.3.4 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Skin Microbiome, 2021 - 2031F |
6.3.5 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Vaginal Microbiome, 2021 - 2031F |
6.4 Ireland Human Microbiome-Based Drugs and Diagnostics Market, By Application Area |
6.4.1 Overview and Analysis |
6.4.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Gastrointestinal Health, 2021 - 2031F |
6.4.3 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Oral Health, 2021 - 2031F |
6.4.4 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Dermatological Disorders, 2021 - 2031F |
6.4.5 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Immune Modulation, 2021 - 2031F |
6.5 Ireland Human Microbiome-Based Drugs and Diagnostics Market, By End Use |
6.5.1 Overview and Analysis |
6.5.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Digestive Disorders, 2021 - 2031F |
6.5.3 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Periodontal Disease, 2021 - 2031F |
6.5.4 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Skin Health, 2021 - 2031F |
6.5.5 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenues & Volume, By Vaginal Health, 2021 - 2031F |
7 Ireland Human Microbiome-Based Drugs and Diagnostics Market Import-Export Trade Statistics |
7.1 Ireland Human Microbiome-Based Drugs and Diagnostics Market Export to Major Countries |
7.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Imports from Major Countries |
8 Ireland Human Microbiome-Based Drugs and Diagnostics Market Key Performance Indicators |
8.1 Number of clinical trials and research studies conducted on microbiome-based drugs and diagnostics |
8.2 Adoption rate of microbiome-based products by healthcare providers |
8.3 Investment in microbiome-based companies and technologies |
8.4 Patient outcomes and improvements in health conditions following the use of microbiome-based therapies |
8.5 Number of partnerships and collaborations in the field of human microbiome-based drugs and diagnostics |
9 Ireland Human Microbiome-Based Drugs and Diagnostics Market - Opportunity Assessment |
9.1 Ireland Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Drug Category, 2021 & 2031F |
9.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Diagnostic Category, 2021 & 2031F |
9.3 Ireland Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Target Organism, 2021 & 2031F |
9.4 Ireland Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By Application Area, 2021 & 2031F |
9.5 Ireland Human Microbiome-Based Drugs and Diagnostics Market Opportunity Assessment, By End Use, 2021 & 2031F |
10 Ireland Human Microbiome-Based Drugs and Diagnostics Market - Competitive Landscape |
10.1 Ireland Human Microbiome-Based Drugs and Diagnostics Market Revenue Share, By Companies, 2024 |
10.2 Ireland Human Microbiome-Based Drugs and Diagnostics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here